Table 4: Hemostatic markers affected by warfarin in NVAF patients not taking warfarin and in control subjects without a history of thrombotic stroke
Marker	Group; mean value (and SD)			Adjusted p value*
	NVAF patients not taking warfarin n = 29	Control subjects without history of stroke n = 31	Difference in means (and 95% CI)
Protein C, µ/mL	0.89  (0.18)	1.10  (0.24)	0.21  ( 0.31, 0.10)	0.012
Protein S, µ/mL	0.83  (0.14)	0.98  (0.17)	0.15  ( 0.23, 0.07)	< 0.001
FPA, nmol/L
All subjects	10.30  (16.70)	7.40  (17.80)	2.90  ( 5.80, 11.60)	0.57
Excluding outliers†	4.00  (2.40)	2.90  (2.30)	1.10  ( 0.19, 2.40)	0.03
	n = 23	n = 29
Prothrombin fragment F1+2, nmol/L
All subjects	1.30  (0.50)	1.80  (0.99)	0.50  ( 0.89, 0.10)	< 0.001
Excluding outliers†	1.20  (0.48)	1.72   (0.97)	0.52  ( 0.90, 0.12)	0.002
	n = 23	n = 29
*Determined by ANOVA, for difference between groups after adjustment for age and sex. †All values of FPA > 10 nmol/L and the corresponding F1+2 values were considered outliers and removed for this analysis (see reference 21).

[Return to text]